Coronado Biosciences +12.4% AH on interim CNDO-201 study

Coronado Biosciences (CNDO) shares jump 12.4% AH after the company releases interim data for a pilot study of oral CNDO-201 to treat autism.

In the first 5 patients that completed the double-blind, randomized, placebo-controlled cross-over study, a statistically significant separation from the placebo in favor of CNDO-201 was demonstrated in 3 measures of the disease. Treatment was well tolerated, the study found.

The study is ongoing and final results are expected in mid-2014.

Comments (1)
  • carabela
    , contributor
    Comments (15) | Send Message
    Coronado is doing trials in a therapy that has been producing results for years to thousands of "patients" in cases where conventional drugs could only offer paliative solutions.
    These results just published are another example of what Helminthic Therapy has to offer.
    I am confident that, if Coronado has learned from its past mistakes concerning previous trials, future results will justify and prove the efficiency of the therapy that many people like us have been following for years.
    I bought about 1 month ago at 1.32$ and I am not selling now as I hope that the share price will reflect eventually the future susccessful results
    Time will tell
    13 Dec 2013, 04:08 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs